Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.
Among the drugs that snagged top spots in EvaluatePharma's annual world preview report, AbbVie's ($ABBV) Humira is slated to remain the biggest global brand through 2020. The inflammatory drug is set to bring in $12.7 billion in 2020--a 15% increase from 2013, when it posted $11 billion in sales.
Despite the fact that copycat versions of Sanofi's ($SNY) top-selling diabetes drug Lantus are on the way, EP expects the powerhouse drug to keep growing, from an estimated $7.59 billion to $10.25 billion. But Lantus is not the only drug staying afloat in the lucrative diabetes pool. Merck's ($MRK) Januvia franchise will also keep a top spot, with worldwide sales projected to reach $6.89 billion in 2020.
Autoimmune drugs will also hold their own, with Amgen's ($AMGN) TNF inhibitor Enbrel enjoying patent protection through 2028 that should ward off generic competitors. Janssen's Remicade, a monoclonal antibody (mAb) therapy for rheumatoid arthritis (RA) and Crohn's disease, will also maintain steady global sales--but a quickly approaching U.S. patent expiration in 2018 could put a damper on things.
continue to read here
Among the drugs that snagged top spots in EvaluatePharma's annual world preview report, AbbVie's ($ABBV) Humira is slated to remain the biggest global brand through 2020. The inflammatory drug is set to bring in $12.7 billion in 2020--a 15% increase from 2013, when it posted $11 billion in sales.
Despite the fact that copycat versions of Sanofi's ($SNY) top-selling diabetes drug Lantus are on the way, EP expects the powerhouse drug to keep growing, from an estimated $7.59 billion to $10.25 billion. But Lantus is not the only drug staying afloat in the lucrative diabetes pool. Merck's ($MRK) Januvia franchise will also keep a top spot, with worldwide sales projected to reach $6.89 billion in 2020.
Autoimmune drugs will also hold their own, with Amgen's ($AMGN) TNF inhibitor Enbrel enjoying patent protection through 2028 that should ward off generic competitors. Janssen's Remicade, a monoclonal antibody (mAb) therapy for rheumatoid arthritis (RA) and Crohn's disease, will also maintain steady global sales--but a quickly approaching U.S. patent expiration in 2018 could put a damper on things.
continue to read here
No comments:
Post a Comment